EZH2 inhibition sensitizes BRG1 and EGFR mutant lung tumors to TopoII inhibitors

Non-small cell lung cancer (NSCLC) is the leading cause of cancer-related death worldwide(1). Chemotherapies such as the topoisomerase II inhibitor (TopoIIi) etoposide effectively reduce disease in a minority of NSCLC patients(2,3); therefore, alternative drug targets, including epigenetic enzymes,...

Ful tanımlama

Kaydedildi:
Detaylı Bibliyografya
Yayımlandı:Nature
Asıl Yazarlar: Fillmore, Christine M., Xu, Chunxiao, Desai, Pooja T., Berry, Joanne M., Rowbotham, Samuel P., Lin, Yi-Jang, Zhang, Haikuo, Marquez, Victor E., Hammerman, Peter S., Wong, Kwok-Kin, Kim, Carla F.
Materyal Türü: Artigo
Dil:Inglês
Baskı/Yayın Bilgisi: 2015
Konular:
Article
Online Erişim:https://ncbi.nlm.nih.gov/pmc/articles/PMC4393352/
https://ncbi.nlm.nih.gov/pubmed/25629630
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/nature14122
Etiketler: Etiketle
Etiket eklenmemiş, İlk siz ekleyin!

Benzer Materyaller